Mode
Text Size
Log in / Sign up
Phase 3 N=416 Randomized Treatment

PCM Cervical Disc System

Radiculopathy · Myelopathy

Enrolled (actual)
416
Serious AEs
30.9%
Results posted
Feb 2013
Primary outcome: Primary: Individual Patient Overall Success — 142; 98 participants

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Anterior Cervical Discectomy and Fusion (ACDF) (Device); PCM Cervical Disc (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
NuVasive
Primary completion
Mar 2010

Outcome Measures

OutcomeResultp-value
PRIMARY
Individual Patient Overall Success
142; 98
SECONDARY
Neck Pain Visual Analog Scale
139; 113
SECONDARY
Mean Neck Pain Visual Analog Scale
26.1; 30.4
SECONDARY
Worst Arm Pain Visual Analog Scale
148; 113
SECONDARY
Mean Worst Arm Pain Visual Analog Scale
24.9; 27.5
SECONDARY
Clinically Significant Improvement on Neck Disability Index (NDI)
149; 114
SECONDARY
Clinically Significant Improvement on Neck Disability Index (NDI)
149; 114
SECONDARY
Mean Neck Disability Index (NDI)
21.8; 25.5
SECONDARY
Clinically Significant Improvement on SF-36 Physical Component Summary (PCS)
133; 98
SECONDARY
Mean SF-36 Physical Component Summary (PCS)
46.6; 45.0
SECONDARY
Clinically Significant Improvement on SF-36 Mental Component Summary (MCS)
87; 75
SECONDARY
Mean SF-36 Mental Component Summary (MCS)
50.3; 49.3
SECONDARY
Dysphagia for Swallowing
8.8; 12.1
SECONDARY
Patient Satisfaction
82.8; 81.4
SECONDARY
Nurick's Classification of Disability (Myelopathy)
185; 148
SECONDARY
Flexion/Extension Range of Motion at the Operative Level
5.7; 0.8

Summary

The PCM Cervical Disc was studied in a prospective, multicenter, randomized FDA-approved investigational device exemption (IDE) clinical trial conducted in the United States to evaluate longitudinal outcomes over 2 years comparatively between the PCM Cervical Disc and anterior cervical discectomy and fusion (ACDF) with allograft and plate. Patients with adjacent or non-adjacent prior fusion were allowed. A total of 416 patients with a degenerated cervical disc at one level from C3-C4 to C7-T1 were enrolled in the clinical trial and 403 were treated. Patients were randomly assigned to be treated either with the PCM Cervical Disc or ACDF.

Eligibility Criteria

Inclusion Criteria

  • Age 18-65 years;
  • Diagnosis of radiculopathy or myelopathy of the cervical spine between C3-4 and C7-T1;
  • Symptomatic at only one level from C3-C4 to C7-T1;
  • Unresponsive to non-operative treatment for six weeks, or has the presence of progressive symptoms or signs of nerve root/spinal cord compression in the face of conservative treatment;
  • Baseline NDI score of ≥30/100;
  • Radiographically determined pathology at level to be treated correlating to primary symptoms, including at least one of the following: decreased disc height, degenerative spondylosis on CT or MRI, or disc herniation;
  • Appropriate for treatment using an anterior surgical approach, including having no more than one previous anterior surgical approach to the cervical spine;
  • Ability and willingness to comply with follow-up regimen; and
  • Written informed consent given by subject or subject's legally authorized representative.

Exclusion Criteria

  • Infection at the site of surgery;
  • History of, or anticipated treatment for, active systemic infection, including HIV infection or hepatitis C;
  • Prior attempted or completed cervical spine surgery, except (1) laminoforaminotomy with less than one-third facetectomy at any level, or (2) a successful single-level anterior cervical fusion;
  • More than one immobile vertebral level between C1-T1 from any cause, including but not limited to congenital abnormalities, osteoarthritic "spontaneous" fusions, and prior cervical spinal fusions;
  • Previous trauma to the C3-T1 levels resulting in significant bony or disco-ligamentous cervical spine injury;
  • Axial neck pain in the absence of other symptoms of radiculopathy or myelopathy justifying the need for surgical intervention;
  • Radiographic confirmation of severe facet joint disease or degeneration.
  • Osteoporosis:
  • Severe diabetes mellitus requiring daily insulin management;
  • Active malignancy: a history of any invasive malignancy (except non-melanoma skin cancer), unless the patient has been treated with curative intent and there have been no clinical signs or symptoms of the malignancy for at least 5 years;
  • Tumor as source of symptoms;
  • Symptomatic DDD or significant cervical spondylosis at two or more levels;
  • Known or suspected allergy to cobalt, chromium, molybdenum, titanium, or polyethylene;
  • Severe myelopathy to the extent that the patient is wheelchair bound;
  • Pregnant (verified in patients of childbearing potential by a negative urine pregnancy test when preadmission testing is obtained), or interested in becoming pregnant during the duration of the study;
  • Autoimmune disorders that impact the musculoskeletal system (e.g., lupus, rheumatoid arthritis; ankylosing spondylitis);
  • Spinal axis disease (thoracic or lumbar) to the extent that surgical consideration is likely anticipated within 6 months after the cervical randomized procedure;
  • Other degenerative joint disease (e.g. shoulder, hip, knee) to the extent that surgical consideration is likely anticipated within 6 months after the cervical randomized procedure;
  • Previous spine surgery within the 6 months preceding the cervical randomized procedure;
  • Current or recent history of substance abuse (drug or alcohol);
  • Morbid obesity, defined as body mass index ("BMI") > 40 or more than 100 lbs. over ideal body weight;
  • Currently using, or planning to use, bone growth stimulators in the cervical spine;
  • Use of any other investigational drug or medical device within the last 30 days prior to surgery
  • Currently a prisoner; or
  • Currently pursuing personal litigation related to the neck or cervical spine injury; however, involvement in worker's compensation related litigation is not a required exclusion.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00578812). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search